COMPANY PROFILE // THE 014 REPORT

Kyverna Therapeutics, Inc.

KYTX (Nasdaq)

Assembled from 4 government sources in 0.4 s

Built from public records at 2026-11-21 19:17 ET. Every figure links to its source. Flags and checks built 2026-11-21 21:55 ET. Sources

FLAGS · DISCLOSURE · SUMMARY

Missing or hidden

  • Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-05-18: a pattern of leadership change.2026-05-18 · source

✓ SEC filings✓ State registrationpossible match✓ Lobbying registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website

No LEI, no SAM registration, no IRS return, no website on record.

Kyverna Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Emeryville, CA; listed as KYTX (Nasdaq).[source] It has filed 69 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] 2 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are GordonMD Global Investments LP, GILEAD SCIENCES, INC., BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-05-18.[source]

0federal award recipients matched by name in USAspending
2lobbying filings name it as client (possible match)
69SEC filings in the last 12 months
$214.8Mheld by its 10 largest 13F holders (as of 2026-06-30)
SEC filings by month, 24 months
2024-12: 02025-01: 42025-02: 12025-03: 52025-04: 102025-05: 22025-06: 82025-07: 22025-08: 22025-09: 12025-10: 22025-11: 42025-12: 102026-01: 22026-02: 92026-03: 122026-04: 112026-05: 132026-06: 12026-07: 32026-08: 32026-09: 12026-10: 12026-11: 32024-122026-11
Flags by level
  • red0
  • amber1
  • info0
Largest 13F holders, value as filed
  • GordonMD Global Investments LP$37.8M
  • GILEAD SCIENCES, INC.$36.8M
  • BlackRock, Inc.$27.9M
  • Bain Capital Life Sciences Investors, LLC$25.7M
  • AIGH Capital Management LLC$24.9M
  • DEERFIELD MANAGEMENT COMPANY, L.P.$17.8M
  • VANGUARD CAPITAL MANAGEMENT LLC$16.9M
  • GEODE CAPITAL MANAGEMENT, LLC$9.4M

RECORD · WEB

Ask about this entity

Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).

PEOPLE · COUNSEL · LINKS

Leadership, advisers and links

Officers and directors (Forms 3, 4, 5)

As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.

Legal counsel, as publicly named

EVERY LIST AND SOURCE · DATED

Checked and clear

26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.

List or sourceResultCheckedWhat matched
OFAC SDN (Treasury)CLEAR2026-11-20
SAM.gov exclusionsCLEAR2026-11-21
HHS-OIG LEIECLEAR2026-11-13
FARA registrants (DOJ)CLEAR2026-11-21
Regulated facility: compliance, penalties and TRI parent (EPA)POSSIBLE MATCH2026-11-18KYVERNA THERAPEUTICS; KYVERNA THERAPEUTICS, INC
Hazardous-waste handler facility (EPA RCRAInfo, sample)CLEAR2026-11-18
Consumer complaints about a company (CFPB)CLEAR2026-11-18
Corporate enforcement action (DOJ, SEC, CFTC, EPA)CLEAR2026-11-18
SEC litigation release (respondent)CLEAR2026-11-18
Federal Reserve Board enforcement action (press release, 2022 onward)CLEAR2026-11-18
Enforcement order against a savings association (OCC, OTS archive to 2011)CLEAR2026-11-18
State environmental enforcement actions (Maryland MDE, Connecticut DEEP)CLEAR2026-11-18
Firm sanctioned or debarred by the IDB Group (incl. cross-debarments by WBG, ADB, EBRD, AfDB as listed by the IDB)CLEAR2026-11-18
UK sanctions designation (FCDO UK Sanctions List)CLEAR2026-11-18
US export screening list party (Consolidated Screening List, ITA)CLEAR2026-11-18
FDA recallCLEAR2026-11-18
FDA import alert or listed firm (Red / Yellow / Green list)CLEAR2026-11-18
Consumer product recall or recalling firm (CPSC, full history)CLEAR2026-11-18
Consumer product recall (CPSC)CLEAR2026-11-18
Vehicle recall, defect investigation or manufacturer (NHTSA ODI)CLEAR2026-11-18
Vehicle recall (NHTSA)CLEAR2026-11-18
FinCEN enforcement action (civil money penalty or consent order, 1999 onward)CLEAR2026-11-18
Union representation election (NLRB)CLEAR2026-11-18
NYC summons against an organization, adjudicated at OATH (all city agencies)CLEAR2026-11-18
Data breach notice to a state Attorney GeneralCLEAR2026-11-18
Data breach notice (California Attorney General)CLEAR2026-11-18

EVERY IDENTIFIER · LINKED

ID crosswalk

IdentifierValueRecord
SEC CIK0001994702source
EIN83-1365441source
NY DOS ID7365306record
Connecticut business ID3508477record
LDA clientpossible match72192record
LDA clientpossible match69525record
Business address (SEC)5980 HORTON STREET, SUITE 200, EMERYVILLE, CAsource

Does not exist in the records we hold: LEI, UEI, FDIC certificate.

EACH FEEDS WATCH

Dates coming up

PEERS BY SIC CODE

Industry context

SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.

#11 of 183
federal dollars
#5 of 183
lobbying filings
#76 of 183
SEC filings in 12 months
#59 of 183
flags

Peers, each with its 014

SHARED PEOPLE · SHARED ADDRESS

Network neighbours

Shared directors and officers

EVERY SOURCE · NEWEST FIRST

One timeline

94 earlier entries

RENDERED FROM THIS PAGE

Relationship graph

GordonMD Global Investments LP · holderGILEAD SCIENCES, INC. · holderBlackRock, Inc. · holderBain Capital Life Sciences Investo · holderAIGH Capital Management LLC · holderAKIN GUMP STRAUSS HAUER & FELD · lobbying firmBROWNSTEIN HYATT FARBER SCHRECK, L · lobbying firmBiddle Warner Weston · officer or directorGEHCHAN NAJI · officer or directorGRASSO MARC · officer or directorJones Ryan Alexander · officer or directorPujols Mayobanex · officer or directorPaul Hastings LLP · counselAlto Neuroscience, Inc. · shared boardAssertio Holdings, Inc. · shared boardBIOMARIN PHARMACEUTICAL INC · shared boardBeam Therapeutics Inc. · shared boardKyverna Therapeutics, Inc.

Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.

DATA MOTION // NEWEST FIRST

What changed

Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.

COUNTS FROM THIS PAGE

Relationships at a glance

10largest institutional holders (13F as filed)
0other entities in the GLEIF ownership tree (ID tier)
0awarding federal agencies
2hiring lobbying firms: possible match: matched by name only, not merged
PRICE · FILINGS · POSTS · NEWS

Market & news

Price
NASDAQ:KYTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
Open in
Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

Financials
Filed figures: published SEC values, each linked to its filing.
Official posts
Links to posts from the company's and agencies' verified accounts: not connected yet.
News
Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER

1. Identity

1confirmed members (SEC registrant + GLEIF ownership tree)
0legal entities (LEI) in the ownership tree
29dated filings and events

8 possible matches held apart, matched by name only, not counted above.

IdentifierValueHow it was resolvedSource
SEC CIK1994702id:sec-anchor: the SEC registrant record of this companySEC EDGAR
Ticker / exchangeKYTX / NasdaqSEC company record: ticker and exchange as listed on the SEC company recordSEC EDGAR
EIN831365441carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001994702SEC EDGAR / IRS
CUSIP501976104carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001994702SEC EDGAR

possible match: matched by name only, not merged (5)

Identifiers carried by records that share the company's exact name. Not merged into the identity above.

IdentifierValueHow it was resolvedSource
LDA client id69525 (KYVERNA THERAPEUTICS, INC. (lobbying via AKIN GUMP STRAUSS HAUER & FELD))name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.'Lobbying Disclosure Act (LDA)
LDA client id72192 (KYVERNA THERAPEUTICS, INC. (lobbying via BROWNSTEIN HYATT FARBER SCHRECK, LLP))name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.'Lobbying Disclosure Act (LDA)
EPA FRS id110071135246 (KYVERNA THERAPEUTICS)name-exact: exact name match to 'Kyverna Therapeutics, Inc.' (no other entity shares the name)EPA ECHO facilities
EPA FRS id110070900952 (KYVERNA THERAPEUTICS INC)name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.'EPA ECHO facilities
EPA FRS id110070900491 (KYVERNA THERAPEUTICS, INC)name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.'EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING

2. Filed figures

Key figures (annual filing)

FigureValuePeriod or as ofSourceBasisRetrievedReport
Net income (loss) (fiscal year ended 2025-12-31)-$161,307,0002025-12-3110-K, XBRL NetIncomeLossas filed2026-11-22 00:17 UTCReport an error
Total assets (at 2025-12-31)$293,826,0002025-12-3110-K, XBRL Assetsas filed2026-11-22 00:17 UTCReport an error
Stockholders' equity (at 2025-12-31)$232,276,0002025-12-3110-K, XBRL StockholdersEquityas filed2026-11-22 00:17 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$124,093,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValueas filed2026-11-22 00:17 UTCReport an error

Company profile facts (SEC)

FigureValuePeriod or as ofSourceBasisRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error
Business address5980 HORTON STREET, SUITE 200, EMERYVILLE, CA2026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profileas filed2026-11-22 00:17 UTCReport an error

Other filed values

FigureValuePeriod or as ofSourceBasisRetrievedReport
Operating cash flow (fiscal year ended 2025-12-31)-$153,712,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivitiesas filed2026-11-22 00:17 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$5,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipmentas filed2026-11-22 00:17 UTCReport an error
Operating lease liabilities (at 2025-12-31)$3,982,0002025-12-3110-K, XBRL OperatingLeaseLiabilityas filed2026-11-22 00:17 UTCReport an error
Form D total offering amount (D filed 2023-11-07)$151,999,9812023-11-07Das filed2026-11-22 00:17 UTCReport an error
Form D total amount sold (D filed 2023-11-07)$151,999,9812023-11-07Das filed2026-11-22 00:17 UTCReport an error
Form D industry groupBiotechnology2023-11-07Das filed2026-11-22 00:17 UTCReport an error
Form D revenue rangeDecline to Disclose2023-11-07Das filed2026-11-22 00:17 UTCReport an error
Form D date of first sale2021-11-092023-11-07Das filed2026-11-22 00:17 UTCReport an error
Plan (welfare, plan no. 501)THE KYVERNA THERAPEUTICS, INC. EMPLOYEE BENEFITS PLAN: 134 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)as filed2026-11-22 00:17 UTCReport an error

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001193125-26-457043

ItemValuePeriodFormFiledAccessionRetrievedReport
Net income (loss)-$41,941,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4570432026-11-22 00:17 UTCReport an error
Interest expense$728,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4570432026-11-22 00:17 UTCReport an error
Cash and cash equivalents$31,818,000at 2026-09-3010-Q2026-11-120001193125-26-4570432026-11-22 00:17 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.

No estimates: every value is as filed and links to the filing it came from.

Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.

NEWEST FIRST · EACH LINKS TO ITS FILING

3. Registration and filing timeline

4 earlier entries

8-K item text, as filed (excerpts)

Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.

POSSIBLE MATCHES · NAME ONLY

6. Lobbying (LDA)

2 lobbying records carry this company's exact name, hiring 2 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.

possible match: matched by name only, not merged (2)

Possible match based on name, not a shared identifier. Compare the records.

POSSIBLE MATCHES · GROUPED BY SOURCE

8. Enforcement by agency

EPA ECHO facilities (3)

possible match: matched by name only, not merged (3)

Possible match based on name, not a shared identifier. Compare the records.

Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.

AS FILED · LARGEST HOLDERS

10. 13F institutional holders

RankHolder (13F filer)Value heldAs ofSourceRetrievedReport
1GordonMD Global Investments LP$37,821,3282026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
2GILEAD SCIENCES, INC.$36,763,7202026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
3BlackRock, Inc.$27,931,1302026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
4Bain Capital Life Sciences Investors, LLC$25,705,3502026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
5AIGH Capital Management LLC$24,910,5522026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
6DEERFIELD MANAGEMENT COMPANY, L.P.$17,820,0002026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
7VANGUARD CAPITAL MANAGEMENT LLC$16,906,2882026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
8GEODE CAPITAL MANAGEMENT, LLC$9,352,5372026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
9Insight Holdings Group, LLC$8,812,4712026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error
10STATE STREET CORP$8,751,6962026-06-30SEC 13F filing2026-11-22 00:17 UTCReport an error

13F as filed: the holder's own report of its position value at the quarter end.

DOL H-1B (LCA) · WARN NOT HELD

12. Labor

MeasureValueAs ofSourceRetrievedReport
Employer name (as filed)Kyverna Therapeutics, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Total worker positions on certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Top job titles (title, LCA count)Associate Director, Medical Engagement Operations (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Wage offered, annualized (n, min, median, max)median $206,000 (range $206,000-$206,000, 1 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error
Worksite statesCA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:17 UTCReport an error

Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.

WARN layoff notices: not held yet.

POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS

13. Permits and local records

3 state and city records carry this company's exact name, from 3 sources. Possible matches only.

Connecticut business registrations (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

ClinicalTrials.gov (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

  • possible matchKyverna Therapeutics · exact name match to 'Kyverna Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h2c587d91d066f6cc Compare

New York corporations (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

WHAT THIS PAGE READ

Sources

As of 2026-11-22 (record built 2026-11-22T00:17:18Z). Sources used: SEC EDGAR, DOL OFLC LCA Disclosure Data, DOL EBSA Form 5500 public datasets, SEC 13F holdings.

Not checked: FTC enforcement actions; DOJ press releases (beyond FARA and the corporate enforcement set); federal and state court records; UCC filings, liens and bankruptcy dockets; IRS automatic revocation list; state annual-report dates; company formation dates (only where a state registry record states one).

JSON · MCP · API

API and agents

The same profile as JSON: GET /company/1994702.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001994702. Every source URL used is listed in the file.

Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.